Eugene Dula, MD
Urology · Tarzana, CANPI 1184694523
Payments from drug & device makers
Across 257 payments — averaging $33.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Pfizer$601
- Blue Earth Diagnostics$439
- Coloplast$397
- Procept Biorobotics Corporation$376
- Rochester Medical Corporation$326
- plus $3K from 28 others
What the payments were for
- Travel & lodging$6478%
- Food & beverage$4,69155%
- Education$3,15537%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $3,721 |
| Pfizer | 24 | $601 |
| Blue Earth Diagnostics | 18 | $439 |
| Coloplast | 24 | $397 |
| Procept Biorobotics Corporation | 4 | $376 |
| Rochester Medical Corporation | 40 | $326 |
| Endo Pharmaceuticals Inc. | 18 | $319 |
| C. R. Bard, Inc. & Subsidiaries | 33 | $317 |
| AbbVie | 11 | $263 |
| Astellas Pharma US Inc | 11 | $221 |
| Myriad Genetic Laboratories, Inc. | 9 | $190 |
| Johnson & Johnson | 8 | $161 |
| Progenics Pharmaceuticals, Inc. | 5 | $126 |
| Antares Pharma, Inc. | 6 | $111 |
| Profound Medical Corp. | 1 | $100 |
| Endo USA, Inc. | 4 | $99 |
| Teleflex LLC | 3 | $85 |
| Telix Pharmaceuticals | 3 | $78 |
| BD | 4 | $64 |
| Sumitomo Pharma America, Inc. | 3 | $62 |
| Boston Scientific | 3 | $54 |
| Dendreon Pharmaceuticals LLC | 2 | $48 |
| Olympus America Inc. | 2 | $48 |
| Myovant Sciences Inc. | 3 | $43 |
| Accord Healthcare, Inc. | 2 | $42 |
| Urogen Pharma, Inc. | 2 | $39 |
| Bard Access Systems, Inc. | 1 | $26 |
| Tolmar Pharmaceuticals, Inc. | 1 | $25 |
| Amgen | 1 | $24 |
| Metuchen Pharmaceuticals | 1 | $20 |
| Axonics, Inc. | 1 | $20 |
| Avadel Specialty Pharmaceuticals, LLC | 1 | $18 |
| ABC Home Medical Supply, Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,492 in reported general payments places this provider in the 70th percentile of 1,324 urology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 91 | $112,015 |
| MyrbetriqMirabegron | 99 | $83,799 |
| Dutasteride | 228 | $11,271 |
| Testosterone | 53 | $8,323 |
| Potassium Citrate ErPotassium Citrate | 66 | $7,614 |
| Tamsulosin Hcl | 477 | $6,702 |
| Silodosin | 52 | $5,627 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 173 | $4,832 |
| Oxybutynin Chloride ErOxybutynin Chloride | 126 | $4,110 |
| Estradiol | 54 | $3,284 |
| Finasteride | 169 | $2,439 |
| Bicalutamide | 41 | $2,355 |
| Testosterone Cypionate | 27 | $1,988 |
| Terazosin Hcl | 52 | $968 |
| NitrofurantoinNitrofurantoin Macrocrystal | 32 | $803 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $62 | $112,01591 claims |
| Astellas Pharma US IncMyrbetriq | $221 | $83,79999 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,324 urology providers in California.
Other urology in Tarzana
- Edward UchioOrange$21.1M
- Stephen FreedlandWest Hollywood$16.7M
- Alec KooTorrance$7.4M
- Karim ChamieLos Angeles$4.3M
- Ralph ClaymanOrange$3.9M
- Siamak DaneshmandLos Angeles$3.5M
- Arnold ChinLos Angeles$3.5M
- Roger LiLoma Linda$2.3M
- John KowalczykLos Angeles$1.8M
- Arie BelldegrunLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.